CoronavirusPhase 1/2MATISNCT04581954
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
A Phase 1/2 study testing Ruxolitinib and Fostamatinib in people with Coronavirus and Covid19, run by Imperial College London at 5 sites in United Kingdom.
Trial summary
The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a two-stage, open-label, randomised controlled trial assessing the efficacy of ruxolitinib (RUX) and fostamatinib (FOS) individually, compared to standard of care in the treatment of COVID-19 pneumonia. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronavirus, Covid19, Pneumonia
- What is being tested?
- Ruxolitinib and Fostamatinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 185 participants
- Where
- 5 sitesUnited Kingdom
- Study dates
- 2 Oct 2020to 2 Sep 2023
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients age ≥ 18 years at screening
- Patients with mild or moderate C19 pneumonia, defined as Grade 3 or 4 severity by the WHO COVID-19 Ordinal Scale by
- Patients meeting criteria: Hospitalization AND SARS-CoV2 infection (clinically suspected* or laboratory-confirmed) AND Radiological change consistent with COVID-19 disease
- C-reactive protein (CRP) greater than or equal to 30mg/L
- Informed consent from patient or personal or professional representative
- No medical history that might, in the opinion of the responsible clinician, put the patient at significant risk if he/she were to participate in the trial
- Agreement to abstain from sexual intercourse or use contraception that is >99% effective for all participants of childbearing potential for 42 days after the last dose of study drug. For male participants, agreement to abstain from sperm donation for 42 days after the last dose of study drug.
- Able to read English. Non-English speakers will be able to join the study. If patients are unable to understand verbal or written information in English - hospital translation services will be requested at the participating site for the participant where possible.
Who cannot join
- Requiring either invasive or non-invasive ventilation including CPAP or high flow nasal oxygen at any point after hospital admission and before baseline not related to a pre-existing condition (e.g. obstructive sleep apnoea)
- Grade ≥ 5 severity on the modified WHO COVID-19 Ordinal Scale, viz. O2 saturation < 90% on ≥ 60% inspired oxygen at baseline; non-invasive ventilation; or invasive mechanical ventilation at any point since hospital admission.
- In the opinion of the investigator, progression to death is inevitable within the next 24 hours, irrespective of the provision of therapy
- Known severe allergic reactions to the investigational agents
- Child Pugh B or C grade hepatic dysfunction
- Use of drugs within the preceding 14 days that are known to interact with any study treatment (FOS or RUX), as listed in the Summary of Product Characteristics
Show all 10Show fewer
- Pregnant or breast feeding
- Any medical condition or concomitant medication that in the opinion of the investigator would compromise subjects' safety or compliance with study procedures.
- Any medical condition which in the opinion of the principal investigator would compromise the scientific integrity of the study
- Pregnant or breast feeding
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United Kingdom5 sites
The Leeds Teaching Hospital - St James University Hospitals NHS Trust
Leeds, LS9 7TF
London North West University Healthcare
London, HA1 3UJ
Imperial College Healthcare NHS Trust
London, W12 0HS
Royal Berkshire NHS Foundation Trust
Reading, RG1 5AN
Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital
Sheffield, S10 2JF
About this study
Official title: Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia
The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a two-stage, open-label, randomised controlled trial assessing the efficacy of ruxolitinib (RUX) and fostamatinib (FOS) individually, compared to standard of care in the treatment of COVID-19 pneumonia. The primary outcome is the proportion of hospitalised patients progressing from mild or moderate to severe COVID-19 pneumonia. Patients are treated for 14 days and will receive follow-up assessment at 7, 14 and 28 days after the first study dose. Patients with mild or moderate COVID-19 pneumonia will be recruited. Initially, n=171 (57 per arm) patients will be recruited in Stage 1. Following interim analysis to assess the efficacy and safety of the treatments, approximately n=285 (95 per arm) will be recruited during Stage 2.
Read the detailed description
COVID-19 pneumonia is characterised by respiratory and multi-organ failure in the context of marked systemic inflammation. It is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2) infection. The hallmark of severe disease is hypoxia and a radiological pattern of acute lung injury that shares features with Acute Respiratory Distress Syndrome (ARDS). Early features of COVID-19 result from host viral response and typically include symptoms such as fever and dry cough. Later features, typically occurring beyond 7 days, are characterised by marked and progressive systemic inflammation, identified by elevations in a plethora of inflammatory molecules such as C-reactive protein, ferritin and IL6. In a subset of patients, hyperinflammatory responses drive acute lung injury and may result in catastrophic multi-organ failure and death.
The aetiology of COVID-19 induced ARDS is incompletely understood but appears to be associated with lung inflammation effected by a monocytic and neutrophilic infiltration, elevated cytokine levels and tissue damage. Elevations in circulating inflammatory molecules are associated with poor prognosis. In particular, the COVID-19 hyperinflammatory response syndrome is associated thrombotic complications which are postulated to drive cardiac dysfunction and microvascular thrombi, suggested by elevations in troponin and D-dimer, respectively. Similar hyperinflammatory responses are also seen in macrophage activation syndromes such as haemophagocytic lymphohistiocytosis, or in the cytokine release syndrome associated with chimeric antigen receptor T cell therapy. Further, preliminary data from China and Italy have shown immediate resolution of symptoms using anti-interleukin-6 agents (anti-IL6) therapy and Janus kinase inhibitors (JAK)/signal transducer and activator of transcription (STAT) inhibitors in patients with severe disease. There may be an early window of opportunity to treat the COVID-19 hyperinflammatory syndrome before acute lung injury leads to organ failure.
There are currently no approved treatments for COVID-19 pneumonia. This is a protocol for a randomised controlled, multi-arm trial of early intervention with inflammatory signal inhibitors.
Study purpose
A number of therapeutic interventions targeting inflammatory signalling might reduce the severity of the inflammatory response phase resulting in amelioration of the lung damage thereby averting respiratory failure and the need for mechanical ventilation. This trial aims to evaluate the efficacy of two inhibitors of key signalling pathways using drugs which are already licensed for use in other clinical indications.
Primary objective
The primary objective is to determine the efficacy of RUX and FOS to reduce the proportion of hospitalised patients progressing from mild/moderate to severe COVID-19 pneumonia. A modified World Health Organization (WHO) COVID-19 Severity Ordinal Scale (COVID-19 Therapeutic Trial Synopsis published 18th February 2020) will be used to grade clinical deterioration from Hospitalised Mild Disease (<5) to Hospitalised Severe Disease (greater than or equal to 5). The modification includes an additional grade for Hospitalised Severe Disease that allows the capture of clinical deterioration in patients for whom escalation in organ support is not offered. Patients are eligible for recruitment to MATIS at grades 3 or 4. These patients stand to gain the greatest benefit from inflammatory signal inhibitors that may ameliorate the cytokine storm and prevent organ failure.
Secondary objectives
- Determine the efficacy of RUX or FOS to reduce mortality
- Determine the efficacy of RUX or FOS to reduce the need for invasive ventilation and/or ECMO
- Determine the efficacy of RUX or FOS to reduce the need for non-invasive ventilation including CPAP or high flow nasal oxygen
- Determine the efficacy of RUX or FOS to reduce the proportion of patients suffering clinically significant oxygen desaturation
- Determine the efficacy of RUX or FOS to reduce the need for renal replacement therapy
- Determine the efficacy of RUX and FOS to reduce the incidence of venous thromboembolism COVID-19 pneumonia
- Determine the efficacy of RUX and FOS to improve the severity of COVID19 pneumonia on a modified WHO COVID19 Ordinal Scale
- Determine the efficacy of RUX or FOS to reduce the level of inflammatory biomarkers
- Determine the efficacy of RUX or FOS to reduce blood ferritin, CRP, LDH and D-dimer
- Determine the efficacy of RUX or FOS to reduce the level of serum creatinine.
- Determine the efficacy of RUX or FOS to reduce duration of hospital admission
- Conditions
- Coronavirus, Covid19, Pneumonia
- Being tested
- Ruxolitinib, Fostamatinib, Standard of care
- Keywords
- coronavirus, covid19, pneumonia, ruxolitinib, fostamatinib
- Medical subject headings
- Coronavirus Infections, COVID-19, Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RuxolitinibDrug
Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action.
FostamatinibDrug
Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
Standard of careOther
Standard of care treatment as per site-level policies and guidelines.
| Study group | Role | What they receive |
|---|---|---|
| Standard of care | Active comparator | Not described Receives: Other: Standard of care |
| Fostamatinib | Active comparator | Not described Receives: Drug: Fostamatinib |
| Ruxolitinib | Active comparator | Not described Receives: Drug: Ruxolitinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression from mild to severe COVID-19 pneumonia within 14 days in hospitalised patients
Patients are recruited at a WHO COVID-19 Severity Score of 3 and 4 and the primary endpoint is the comparison of patients whose COVID-19 pneumonia progresses to a severity score ≥ 5 on the modified WHO Ordinal Scale. Specifically, the primary endpoint is met when the following are recorded within 14 days:
- Death
- Requirement for invasive ventilation
- Requirement for non-invasive ventilation including CPAP or high flow nasal oxygen
- O2 saturation < 90% on ≥60% inspired oxygen
Measured: Day 14
Secondary outcomes (26)
Mortality
all cause mortality
Measured: Day 14
Mortality
all cause mortality
Measured: Day 28
Invasive ventilation
Measured: Day 14
Invasive ventilation
Measured: Day 28
Non-invasive ventilation including CPAP and high flow nasal oxygen
Measured: Day 14
Non-invasive ventilation including CPAP and high flow nasal oxygen
Measured: Day 28
Renal replacement therapy
Measured: Day 14
Renal replacement therapy
Measured: Day 28
Venous Thromboembolism
Measured: Day 14
Venous Thromboembolism
Measured: Day 28
Serum Creatinine
Measured: Day 14
Serum Creatinine
Measured: Day 28
Length of stay
Measured: Day 28
Serious Adverse Events
Measured: Day 28
Serious Adverse Reactions
Measured: Day 28
Treatment discontinuation
Measured: Day 14
Change in severity from the modified WHO COVID-19 ordinal scale
Measured: Day 14
Change in severity from the modified WHO COVID-19 ordinal scale
Measured: Day 28
C-Reactive protein
Measured: Day 14
C-Reactive protein
Measured: Day 28
lactate dehydrogenase
Measured: Day 14
lactate dehydrogenase
Measured: Da 28
ferritin
Measured: Day 14
ferritin
Measured: Da 28
d-dimer
Measured: Day 14
d-dimer
Measured: Day 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2020
- Study start2 Oct 2020
- Primary completion30 Nov 2022
- Study completion2 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for CoronavirusStudies of the same condition, open and under way.
- More trials run by Imperial College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 185 participants (actual)
Sponsor and investigators
- Lead sponsor
- Imperial College London
- Sponsor type
- University, hospital or other
- Collaborators
- Imperial College Healthcare NHS Trust, Rigel Pharmaceuticals, Novartis
- Responsible party
- Sponsor
- Investigators
- Nichola Cooper, Principal investigator, Imperial College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04581954
- Sponsor's protocol ID
- 20HH5926
- Other IDs
- 2020-001750-22
- Acronym
- MATIS
- Status last verified
- Nov 2025
- First submitted
- 5 Oct 2020
- Last updated
- 18 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified participant-level data (excluding free text fields) and supporting documentation (including the MATIS study protocol, Statistical Analysis Plan and data dictionary) can be made available upon reasonable request from the corresponding author (n.cooper@imperial.ac.uk) for the purposes of scientific research including secondary analysis of the data or for individual participant meta-analysis with appropriate human research ethics approvals and data transfer agreements in place
Publications
Hazell L, Pillay C, Cornelius V, Phillips R, Charania A, Wason J, Cherlin S, Savic S, Whittington A, Neelakantan P, Collini P, Cook L, Willicome M, Milojkovic D, Kon OM, Youngstein T, Innes A, Thursz M, Cooke GS, Vergis N, Cooper N. Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic. BMJ Open. 2026 Feb 5;16(2):e100583. doi: 10.1136/bmjopen-2025-100583.
PubMed 41644167Vergis N, Phillips R, Cornelius V, Katsarou A, Youngstein T, Cook L, Willicombe M, Pilay C, Shturova T, Almonte M, Charania A, Turner R, Kon OM, Cooke G, Thursz M, Cherlin S, Wason J, Milojkovic D, Innes AJ, Cooper N. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Apr 12;22(1):270. doi: 10.1186/s13063-021-05190-z.
PubMed 33845867
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia
- ClinicalTrials.gov ID
- NCT04581954
- Acronym / sponsor ID
- MATIS / 20HH5926
- Conditions
- Coronavirus, Covid19, Pneumonia
- Keywords
- coronavirus, covid19, pneumonia, ruxolitinib, fostamatinib
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 185 participants (actual)
- Lead sponsor
- Imperial College LondonUniversity, hospital or other
- Collaborators
- Imperial College Healthcare NHS Trust, Rigel Pharmaceuticals, Novartis
- Study start
- 2 Oct 2020 (actual)
- Primary completion
- 30 Nov 2022 (actual)
- Study completion
- 2 Sep 2023 (actual)
- First posted
- 9 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a two-stage, open-label, randomised controlled trial assessing the efficacy of ruxolitinib (RUX) and fostamatinib (FOS) individually, compared to standard of care in the treatment of COVID-19 pneumonia. The primary outcome is the proportion of hospitalised patients progressing from mild or moderate to severe COVID-19 pneumonia. Patients are treated for 14 days and will receive follow-up assessment at 7, 14 and 28 days after the first study dose. Patients with mild or moderate COVID-19 pneumonia will be recruited. Initially, n=171 (57 per arm) patients will be recruited in Stage 1. Following interim analysis to assess the efficacy and safety of the treatments, approximately n=285 (95 per arm) will be recruited during Stage 2.
Detailed description
COVID-19 pneumonia is characterised by respiratory and multi-organ failure in the context of marked systemic inflammation. It is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2) infection. The hallmark of severe disease is hypoxia and a radiological pattern of acute lung injury that shares features with Acute Respiratory Distress Syndrome (ARDS). Early features of COVID-19 result from host viral response and typically include symptoms such as fever and dry cough. Later features, typically occurring beyond 7 days, are characterised by marked and progressive systemic inflammation, identified by elevations in a plethora of inflammatory molecules such as C-reactive protein, ferritin and IL6. In a subset of patients, hyperinflammatory responses drive acute lung injury and may result in catastrophic multi-organ failure and death.
The aetiology of COVID-19 induced ARDS is incompletely understood but appears to be associated with lung inflammation effected by a monocytic and neutrophilic infiltration, elevated cytokine levels and tissue damage. Elevations in circulating inflammatory molecules are associated with poor prognosis. In particular, the COVID-19 hyperinflammatory response syndrome is associated thrombotic complications which are postulated to drive cardiac dysfunction and microvascular thrombi, suggested by elevations in troponin and D-dimer, respectively. Similar hyperinflammatory responses are also seen in macrophage activation syndromes such as haemophagocytic lymphohistiocytosis, or in the cytokine release syndrome associated with chimeric antigen receptor T cell therapy. Further, preliminary data from China and Italy have shown immediate resolution of symptoms using anti-interleukin-6 agents (anti-IL6) therapy and Janus kinase inhibitors (JAK)/signal transducer and activator of transcription (STAT) inhibitors in patients with severe disease. There may be an early window of opportunity to treat the COVID-19 hyperinflammatory syndrome before acute lung injury leads to organ failure.
There are currently no approved treatments for COVID-19 pneumonia. This is a protocol for a randomised controlled, multi-arm trial of early intervention with inflammatory signal inhibitors.
Study purpose
A number of therapeutic interventions targeting inflammatory signalling might reduce the severity of the inflammatory response phase resulting in amelioration of the lung damage thereby averting respiratory failure and the need for mechanical ventilation. This trial aims to evaluate the efficacy of two inhibitors of key signalling pathways using drugs which are already licensed for use in other clinical indications.
Primary objective
The primary objective is to determine the efficacy of RUX and FOS to reduce the proportion of hospitalised patients progressing from mild/moderate to severe COVID-19 pneumonia. A modified World Health Organization (WHO) COVID-19 Severity Ordinal Scale (COVID-19 Therapeutic Trial Synopsis published 18th February 2020) will be used to grade clinical deterioration from Hospitalised Mild Disease (<5) to Hospitalised Severe Disease (greater than or equal to 5). The modification includes an additional grade for Hospitalised Severe Disease that allows the capture of clinical deterioration in patients for whom escalation in organ support is not offered. Patients are eligible for recruitment to MATIS at grades 3 or 4. These patients stand to gain the greatest benefit from inflammatory signal inhibitors that may ameliorate the cytokine storm and prevent organ failure.
Secondary objectives
- Determine the efficacy of RUX or FOS to reduce mortality
- Determine the efficacy of RUX or FOS to reduce the need for invasive ventilation and/or ECMO
- Determine the efficacy of RUX or FOS to reduce the need for non-invasive ventilation including CPAP or high flow nasal oxygen
- Determine the efficacy of RUX or FOS to reduce the proportion of patients suffering clinically significant oxygen desaturation
- Determine the efficacy of RUX or FOS to reduce the need for renal replacement therapy
- Determine the efficacy of RUX and FOS to reduce the incidence of venous thromboembolism COVID-19 pneumonia
- Determine the efficacy of RUX and FOS to improve the severity of COVID19 pneumonia on a modified WHO COVID19 Ordinal Scale
- Determine the efficacy of RUX or FOS to reduce the level of inflammatory biomarkers
- Determine the efficacy of RUX or FOS to reduce blood ferritin, CRP, LDH and D-dimer
- Determine the efficacy of RUX or FOS to reduce the level of serum creatinine.
- Determine the efficacy of RUX or FOS to reduce duration of hospital admission
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Standard of care | Active comparator | Other: Standard of care |
| Fostamatinib | Active comparator | Drug: Fostamatinib |
| Ruxolitinib | Active comparator | Drug: Ruxolitinib |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Patients age ≥ 18 years at screening
- Patients with mild or moderate C19 pneumonia, defined as Grade 3 or 4 severity by the WHO COVID-19 Ordinal Scale by
- Patients meeting criteria: Hospitalization AND SARS-CoV2 infection (clinically suspected* or laboratory-confirmed) AND Radiological change consistent with COVID-19 disease
- C-reactive protein (CRP) greater than or equal to 30mg/L
- Informed consent from patient or personal or professional representative
Key exclusion criteria (10 listed)
- Requiring either invasive or non-invasive ventilation including CPAP or high flow nasal oxygen at any point after hospital admission and before baseline not related to a pre-existing condition (e.g. obstructive sleep apnoea)
- Grade ≥ 5 severity on the modified WHO COVID-19 Ordinal Scale, viz. O2 saturation < 90% on ≥ 60% inspired oxygen at baseline; non-invasive ventilation; or invasive mechanical ventilation at any point since hospital admission.
- In the opinion of the investigator, progression to death is inevitable within the next 24 hours, irrespective of the provision of therapy
- Known severe allergic reactions to the investigational agents
- Child Pugh B or C grade hepatic dysfunction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RuxolitinibRuxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action. | Drug | Ruxolitinib |
| FostamatinibFostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP). | Drug | Fostamatinib |
| Standard of careStandard of care treatment as per site-level policies and guidelines. | Other | Standard of care |
Primary outcome
Progression from mild to severe COVID-19 pneumonia within 14 days in hospitalised patients
Time frame: Day 14
Patients are recruited at a WHO COVID-19 Severity Score of 3 and 4 and the primary endpoint is the comparison of patients whose COVID-19 pneumonia progresses to a severity score ≥ 5 on the modified WHO Ordinal Scale. Specifically, the primary endpoint is met when the following are recorded within 14 days: * Death * Requirement for invasive ventilation * Requirement for non-invasive ventilation including CPAP or high flow nasal oxygen * O2 saturation < 90% on ≥60% inspired oxygen
26 secondary outcomes
Mortality
Time frame: Day 14
Mortality
Time frame: Day 28
Invasive ventilation
Time frame: Day 14
Invasive ventilation
Time frame: Day 28
Non-invasive ventilation including CPAP and high flow nasal oxygen
Time frame: Day 14
Non-invasive ventilation including CPAP and high flow nasal oxygen
Time frame: Day 28
Renal replacement therapy
Time frame: Day 14
Renal replacement therapy
Time frame: Day 28
Venous Thromboembolism
Time frame: Day 14
Venous Thromboembolism
Time frame: Day 28
Serum Creatinine
Time frame: Day 14
Serum Creatinine
Time frame: Day 28
Length of stay
Time frame: Day 28
Serious Adverse Events
Time frame: Day 28
Serious Adverse Reactions
Time frame: Day 28
Treatment discontinuation
Time frame: Day 14
Change in severity from the modified WHO COVID-19 ordinal scale
Time frame: Day 14
Change in severity from the modified WHO COVID-19 ordinal scale
Time frame: Day 28
C-Reactive protein
Time frame: Day 14
C-Reactive protein
Time frame: Day 28
lactate dehydrogenase
Time frame: Day 14
lactate dehydrogenase
Time frame: Da 28
ferritin
Time frame: Day 14
ferritin
Time frame: Da 28
d-dimer
Time frame: Day 14
d-dimer
Time frame: Day 28
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
- Derived from this study: PubMed 41644167Hazell L, Pillay C, Cornelius V, Phillips R, Charania A, Wason J, Cherlin S, Savic S, Whittington A, Neelakantan P, Collini P, Cook L, Willicome M, Milojkovic D, Kon OM, Youngstein T, Innes A, Thursz M, Cooke GS, Vergis N, Cooper N. Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic. BMJ Open. 2026 Feb 5;16(2):e100583. doi: 10.1136/bmjopen-2025-100583.
- Derived from this study: PubMed 33845867Vergis N, Phillips R, Cornelius V, Katsarou A, Youngstein T, Cook L, Willicombe M, Pilay C, Shturova T, Almonte M, Charania A, Turner R, Kon OM, Cooke G, Thursz M, Cherlin S, Wason J, Milojkovic D, Innes AJ, Cooper N. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Apr 12;22(1):270. doi: 10.1186/s13063-021-05190-z.
- Individual participant dataSharing planned: Yes. De-identified participant-level data (excluding free text fields) and supporting documentation (including the MATIS study protocol, Statistical Analysis Plan and data dictionary) can be made available upon reasonable request from the corresponding author (n.cooper@imperial.ac.uk) for the purposes of scientific research including secondary analysis of the data or for individual participant meta-analysis with appropriate human research ethics approvals and data transfer agreements in place
Related trials for Coronavirus
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nichola Cooper principal investigator
Imperial College London
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Ruxolitinib and Fostamatinib in people with Coronavirus and Covid19, run by Imperial College London at 5 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression from mild to severe COVID-19 pneumonia within 14 days in hospitalised patients (time frame: Day 14). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04581954, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.